Clinical trial

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

NCT07434518

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Adebrelimab (PD-L1 inhibitor) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeOBSERVATIONAL

Start date2026-01-27

PhaseN/A

Conditions

Small Cell Lung Cancer (SCLC)unresolved

Interventions

Adebrelimab (PD-L1 inhibitor)BIOLOGICAL

Sponsors & collaborators

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicinelead sponsor

Shanghai Pulmonary Hospital, Shanghai, Chinacollaborator

Shanghai Chest Hospital of Shanghai Jiao Tong Universitycollaborator

Shanghai 10th People's Hospitalcollaborator

Shanghai Zhongshan Hospitalcollaborator

Huashan Hospitalcollaborator

RenJi Hospitalcollaborator

Shanghai Tongji Hospital, Tongji University School of Medicinecollaborator

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07434518 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.